REGENXBIO Inc. Debt Securities, Available-for-sale
REGENXBIO Inc. (RGNX) had Debt Securities, Available-for-sale of $69.03 million as of 2026-06-30, per its 10-Q filed 2026-08-06.
Financial Statements › Balance Sheet › Assets
us-gaap:AvailableForSaleSecuritiesDebtSecurities · last filed 2026-08-06
- 2026-06-30: Debt Securities, Available-for-sale $69.03M.
- 2026-03-31: Debt Securities, Available-for-sale $135.26M.
- 2025-12-31: Debt Securities, Available-for-sale $206.39M.
- 2025-09-30: Debt Securities, Available-for-sale $243.24M.
| Period end | Debt Securities, Available-for-sale |
|---|---|
| 2026-06-30 | $69.03M 10-Q · filed 2026-08-06 |
| 2026-03-31 | $135.26M 10-Q · filed 2026-05-14 |
| 2025-12-31 | $206.39M 10-Q · filed 2026-08-06 |
| 2025-09-30 | $243.24M 10-Q · filed 2025-11-06 |
| 2025-06-30 | $284.04M 10-Q · filed 2025-08-07 |
| 2025-03-31 | $142.62M 10-Q · filed 2025-05-12 |
| 2024-12-31 | $187.34M 10-K · filed 2026-03-05 |
| 2024-09-30 | $221.95M 10-Q · filed 2024-11-06 |
| 2024-06-30 | $269.54M 10-Q · filed 2024-08-01 |
| 2024-03-31 | $267.54M 10-Q · filed 2024-05-08 |
| 2023-12-31 | $279.61M 10-K · filed 2025-03-13 |
| 2023-09-30 | $311.48M 10-Q · filed 2023-11-08 |
| 2023-06-30 | $346.78M 10-Q · filed 2023-08-02 |
| 2023-03-31 | $403.44M 10-Q · filed 2023-05-03 |
| 2022-12-31 | $468.25M 10-K · filed 2024-02-27 |
| 2022-09-30 | $498.47M 10-Q · filed 2022-11-03 |
| 2022-06-30 | $560.66M 10-Q · filed 2022-08-03 |
| 2022-03-31 | $572.92M 10-Q · filed 2022-05-04 |
| 2021-12-31 | $504.14M 10-K · filed 2023-02-28 |
| 2021-09-30 | $305.11M 10-Q · filed 2021-11-02 |
| 2021-06-30 | $335.88M 10-Q · filed 2021-08-09 |
| 2021-03-31 | $365.00M 10-Q · filed 2021-05-05 |
| 2020-12-31 | $184.12M 10-K · filed 2022-03-01 |
| 2020-09-30 | $196.58M 10-Q · filed 2020-11-04 |
| 2020-06-30 | $245.02M 10-Q · filed 2020-08-06 |
| 2020-03-31 | $287.21M 10-Q · filed 2020-05-07 |
| 2019-12-31 | $330.48M 10-K · filed 2021-03-01 |
| 2019-09-30 | $337.53M 10-Q · filed 2019-11-05 |
| 2019-06-30 | $394.55M 10-Q · filed 2019-08-07 |
| 2019-03-31 | $388.46M 10-Q · filed 2019-05-07 |
| 2018-12-31 | $395.02M 10-K · filed 2020-02-26 |
| 2018-09-30 | $332.46M 10-Q · filed 2018-11-07 |
| 2018-06-30 | $199.40M 10-Q · filed 2018-08-08 |
| 2017-12-31 | $129.74M 10-K · filed 2019-02-27 |
| 2015-09-30 | $19.04M 10-Q · filed 2015-11-05 |
| 2014-12-31 | $0.00 10-Q · filed 2015-11-05 |
Similar stocks
| Stock Name | Country | Market Cap | PE Ratio |
|---|---|---|---|
| Entera Bio Ltd. (ENTX) | $0.485B | ||
| Tectonic Therapeutic, Inc. (TECX) | United States | $0.469B | -7.68 |
| Autolus Therapeutics plc (AUTL) | $0.506B | -1.52 | |
| Eikon Therapeutics, Inc. (EIKN) | United States | $0.446B | |
| Kyverna Therapeutics, Inc. (KYTX) | United States | $0.434B | -3.60 |
| Editas Medicine, Inc. (EDIT) | United States | $0.424B | -4.29 |
| Scribe Therapeutics, Inc. (SCTX) | United States | $0.410B | |
| Prime Medicine, Inc. (PRME) | United States | $0.557B | -3.54 |
| Zura Bio Ltd (ZURA) | $0.398B | -6.56 | |
| Surrozen, Inc./DE (SRZN) | United States | $0.395B |